The high of MDMA (a.k.a.
Mind Medicine has presented positive topline data in Basel, Switzerland in April from a double-blind, investigator-initiated trial evaluating lysergide (LSD) in the treatment of Major Depressive...
In 1943, Swiss chemist Albert Hofmann took the first LSD trip.
A team of scientists has developed LSD-like compounds that fit into the 5HT2a receptor – the main target of substances such as LSD and psilocybin.
Data from a collaborative study between the University Hospital Basel (UHB) and MindMed supports the clinical development of MindMed’s proprietary MM-120 product candidate – a pharmacologically...
Biopharmaceutical company MindMed has dosed the first patient in its Phase 2b Trial of its pharmaceutically optimised form of LSD – MM-120 – in GAD.
Ceruvia Lifesciences has submitted an FDA Investigational New Drug (IND) Application for its NYPRG-101 Migraine Prevention Program.
Freedom to Operate has published its new study that can be used to fight back against anyone attempting to patent a polymorphic form of LSD and...
Findings from a study comparing the acute effects of the two compounds suggest that 20 mg psilocybin is equivalent to 100 μg LSD, and 30 mg...
A recent study testing the impact of microdosing LSD has suggested the practice has no therapeutic or cognitive effects.
